At Delaware’s recent DNA Life Science Conference, experts highlighted the growing threat of China potentially overtaking the U.S. in biotechnology, particularly amid federal funding cuts and supply chain challenges. With biopharma companies facing a projected $350 billion revenue loss from patent expirations by 2032, there’s increasing pressure to innovate or acquire new drugs. Caitlin Frazier of the National Security Commission on Emerging Biotechnology stressed that reliance on past U.S. leadership is risky. Delaware Governor Matt Meyer expressed ambitions to boost the state’s innovation profile, citing Merck’s new facility in Wilmington as a key investment due to the state’s favorable environment for biotech growth and collaboration.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://delawarebusinesstimes.com/insider-only/delaware-advocates-for-biotech/
